RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsized, full-service contract research organization (CRO), today announced two key executive promotions. Dave Bowser was promoted to Chief Operating Officer, leveraging his experience and his team of industry-leading therapeutic leaders to further drive an exceptional customer experience around the globe. Sara Davis was promoted to Chief Commercial Officer, extending the momentum she has driven building and leading a world-class team and delivering on industry-leading growth.
These appointments follow a period of record growth for Worldwide. Since Bowser and Davis joined, the company has extended its focus on central nervous system, rare disease, and cardiology therapies to include oncology and metabolic disease research; expanded its Phase I-IV services to include real-world evidence; and recruited additional top talent globally. Today, more than 2,000 Worldwide professionals meet the challenges of even the largest, most-difficult programs – executing predictable, successful studies across the U.S., Europe, Latin America, and Asia-Pacific.
“Success like ours takes the commitment of thousands of team members who work with passion and purpose every day to improve lives, and our global clinical development and commercial operations are a big part of the equation,” added Peter Benton, president and CEO for Worldwide. “It has been, and remains, a true pleasure to work with Dave and Sara to tackle the challenges and opportunities that come with building Worldwide into the world’s best midsized CRO.”
Bowser joined Worldwide in 2015 to lead the project management function before taking an expanded role to lead the newly formed Global Clinical Development (GCD) team. Since that time, he has successfully built a strong organization that has delivered improvements across all business metrics to support an exceptional customer and employee experience. Customer feedback recently earned Worldwide the coveted CRO Leadership Awards for capabilities, compatibility, expertise, reliability, and quality for the eighth consecutive year. And, average employee turnover is well below the industry average.
Of his appointment, Bowser said, "I am proud of the work we have done to ensure Worldwide ticks all the boxes for small and midsized pharmas and biotechs seeking support for complex trials, including exceptional scientific and medical expertise, quality data, incredible talent, and a collaborative company culture. I’m delighted to step into the COO role and, working with my team, double down on delivering superior, frictionless customer experiences at every touch point.”
Davis joined Worldwide in 2018 as Senior Vice President of Business Development for the U.S. region and quickly accelerated Worldwide’s momentum – earning a promotion to Executive Vice President of Global Business Development. Since that time, with a focus on team, culture, partnership, empowerment, and the person behind the professional, Davis has built a data-driven, world-class commercial team that has delivered industry-leading growth.
“When I joined Worldwide, pharma and biotech sponsors were telling us they had trouble gaining needed expertise, personnel, and resources from large, consolidating CROs,” said Davis. “I’m proud of the work we have done to deliver on our brand promise of the leaders in scientific and operational expertise, flexibility, innovation, personal service and executive support, and engagement this market demands of its CRO partner. Today, as Chief Commercial Officer, I’m looking forward to working with our team to accelerate our momentum and add even more value to our customers than any of our peers.”
Meet the Worldwide leadership team here.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.